# Surufatinib With or Wothout Immunotherapy for Advanced Colorectal Cancer in Later Line

> **NCT05372198** · PHASE2 · UNKNOWN · sponsor: **Hubei Cancer Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Colorectal Neoplasms

## Interventions

- **DRUG:** Chohort 1: Surufatinib
- **DRUG:** Chohort 2: Immunotherapy
- **DRUG:** Chohort 2: Surufatinib

## Key facts

- **NCT ID:** NCT05372198
- **Lead sponsor:** Hubei Cancer Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-03-30
- **Primary completion:** 2024-01
- **Final completion:** 2024-12
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-11-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05372198

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05372198, "Surufatinib With or Wothout Immunotherapy for Advanced Colorectal Cancer in Later Line". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05372198. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*